Novavax NVAX is actually lining up pretty well... from about 240, it tanked to 40, and on Friday, it gained 11% to close the week at 57.15.
This caught my attention as it cleanly broke out of trendlines, breaking out also from a bearish divergence, on BOTH the weekly and daily chart.
IMHO, it appears to be in technical and fractal alignment.
Weekly chart...
Tonix is a producer of the TNX-801 vaccine, effective against Smallpox and Monkeypox.
But that`s not all!
They have a strong balance sheet, Cash and Cash Equivalents Totaled Approximately $140 Million VS its mk cap of only $44.03Mil.
Seth Lederman, M.D., Chief Executive Officer of Tonix: “Tonix is making meaningful strides developing our rich portfolio of high...
GOVX GeoVax Labs is a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer.
GeoVax Labs will report Q1 2022 financial results on April 27.
Jason McCarthy from Maxim Group has a $10.00 price target for GOVX.
The stock is now $1.01.
Market Cap of only 7.23Mil.
This is a 4X upside potential short term stock in my opinion.
on weekly we can see bearish divergence on RSI. there is also possible h&s forming. we have also fundemantals about rigged vaccine trials for emergency authorization acceptance, vaccine deaths piling up and big shareholders of Pfizer dumping their stock.
sell now!
first profit target 32$
second profit target 1$
novavax blew up after announcing it was making a covid vaccine. they eventually parléd this into a montly uptrend that lasted until september '21. since then it has seen a major decline. the stock is attempting to end that now, or at least find a temporary rally from new multi year lows. this could lead to a short squeeze zipping the price back up towards weekly...
They have at their disposal the technical analysis of Novacyt, it has great bullish potential, they have marked resistance and support.
I hope it will help you.
Sincerely, L.E.D. In Spain on 01/20/2022
I made a personal TA on NYSE:PFE using FIB retracements to define when to buy the current pullback reversal.
PFE is currently in a very clear uptrend an its previous pullbacks "reversed" at aroung 50%-61.8% FIB so i think that this current pullback is going to reverse at around 50%.
Before buying:
Check Rsi bounceoff and SMA positionning to form a...
Analyst Vernon Bernardino from H.C. Wainwright reiterated a buy rating and $19 price target on ARDS: "the cocktail binds to the S2 spike protein subunit, which mediates viral cell membrane fusion in SARS-CoV-2 variants and also binds to the omicron variant with no loss in affinity compared to the original Wuhan strain."
Aridis Pharmaceuticals Inc 's monoclonal...
Adagio Therapeutics announced its lead monoclonal antibody has neutralization activity against the Omicron variant of SARS-CoV-2.
Adagio is evaluating ADG20 in its global Phase 2/3 clinical trials for prevention and treatment of COVID-19.
Adagio is engaging with the FDA regarding protocol updates to its global Phase 2/3 clinical trials.
My price target is...
The chart speaks for itself: ARDS is in a massive bullish divergence at all time low levels from which can explode anytime soon!
Recently, analyst Vernon Bernardino from H.C. Wainwright, who reiterated a buy rating and $19 price target on ARDS , told investors that Aridis Pharmaceuticals Inc 's monoclonal Covid-19 Antibody Cocktail is potentially First-in-Class...
first of all thanks for stopping by.. This text below will be posted on every timeframe
Until now, not much was known about Novavax because it was Moderna or Pfizer what was on the news and media, but now NOVAVAX has been in the news and so that's why the chart popped up on my radar .
On the big picture I'm looking at the 2 monthly chart
To remove some noise and...
first of all thanks for stopping by.. This text below will be posted on every timeframe
Until now, not much was known about Novavax because it was Moderna or Pfizer what was on the news and media, but now NOVAVAX has been in the news and so that's why the chart popped up on my radar .
On the big picture I'm looking at the 2 monthly chart
To remove some noise and...
first of all thanks for stopping by.. This text below will be posted on every timeframe
Until now, not much was known about Novavax because it was Moderna or Pfizer what was on the news and media, but now NOVAVAX has been in the news and so that's why the chart popped up on my radar .
On the big picture I'm looking at the 2 monthly chart
To remove some noise and...
Arcturus Therapeutics Holdings Inc. $ARCT is set to be EBITDA positive in 2022 with a massive change in its revenue from 24.05M in 2021 to 326.44M in 2022. This is 12.57x increase in revenue. These numbers are estimates, but even with a large error margin we should see a drastic change in the price. Moreover, the decline from ATH was 80% and the price has been in...
New Data suggest COVAXIN (BBV152) may provide protection against current and future variants!
data from a Phase 3 trial that included nearly 25,800 participants: 77.8% overall efficacy, 93.4% efficacy against severe illness and 65.2% efficacy against the Delta variant.
52 Week Range 0.28 - 18.77
My price target is the 10.30usd resistance.
With the small rise of pox news going on in the U.S., be it the second case of monkeypox this year , to smallpox vials found at a vaccine research facility in Pennsylvania, it brings to question as to whether or not health companies that have the capability to manufacture vaccines, treatments, and test kits against smallpox will be the new growth sector of...
If you haven`t bought at my first call, when PFE was $40:
Than you should know that Pfizer’s vaccine with BioNTech SE is on track to be the best-selling drug product on a yearly basis and received backing from a European regulatory panel on Thursday to expand its use into children as young as five.
Still low PE Ratio (TTM) 15.42
Decent Forward Dividend &...
